253 related articles for article (PubMed ID: 28284329)
1. Soluble CD40 ligand contributes to blood-brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder.
Masuda H; Mori M; Uchida T; Uzawa A; Ohtani R; Kuwabara S
J Neuroimmunol; 2017 Apr; 305():102-107. PubMed ID: 28284329
[TBL] [Abstract][Full Text] [Related]
2. Different roles of soluble CD40 ligand in central nervous system damage.
Du L; Chang H; Wei Y; Zhang X; Yin L
Neurol Res; 2020 May; 42(5):372-378. PubMed ID: 32178599
[No Abstract] [Full Text] [Related]
3. Impact of blood-brain barrier disruption on newly diagnosed neuromyelitis optica spectrum disorder symptoms and prognosis.
Liang S; Qin Q; Tang Y; Liao W; Yang Y; He J; Li L
Ann Palliat Med; 2020 Mar; 9(2):324-330. PubMed ID: 32268769
[TBL] [Abstract][Full Text] [Related]
4. Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: Their possible role on blood-brain barrier disruption.
Uchida T; Mori M; Uzawa A; Masuda H; Muto M; Ohtani R; Kuwabara S
Mult Scler; 2017 Jul; 23(8):1072-1084. PubMed ID: 27682231
[TBL] [Abstract][Full Text] [Related]
5. Blood-brain barrier disruption is more severe in neuromyelitis optica than in multiple sclerosis and correlates with clinical disability.
Tomizawa Y; Yokoyama K; Saiki S; Takahashi T; Matsuoka J; Hattori N
J Int Med Res; 2012; 40(4):1483-91. PubMed ID: 22971500
[TBL] [Abstract][Full Text] [Related]
6. Resolution of inflammation in neuromyelitis optica spectrum disorders.
Wang X; Jiao W; Lin M; Lu C; Liu C; Wang Y; Ma D; Wang X; Yin P; Feng J; Zhu J; Zhu M
Mult Scler Relat Disord; 2019 Jan; 27():34-41. PubMed ID: 30300851
[TBL] [Abstract][Full Text] [Related]
7. Increased cerebrospinal fluid progranulin correlates with interleukin-6 in the acute phase of neuromyelitis optica spectrum disorder.
Kimura A; Takemura M; Saito K; Serrero G; Yoshikura N; Hayashi Y; Inuzuka T
J Neuroimmunol; 2017 Apr; 305():175-181. PubMed ID: 28100408
[TBL] [Abstract][Full Text] [Related]
8. Markedly elevated soluble intercellular adhesion molecule 1, soluble vascular cell adhesion molecule 1 levels, and blood-brain barrier breakdown in neuromyelitis optica.
Uzawa A; Mori M; Masuda S; Kuwabara S
Arch Neurol; 2011 Jul; 68(7):913-7. PubMed ID: 21747031
[TBL] [Abstract][Full Text] [Related]
9. Clinical Features of Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders.
Chen H; Liu SM; Zhang XX; Liu YO; Li SZ; Liu Z; Dong HQ
Chin Med J (Engl); 2016 Sep; 129(17):2079-84. PubMed ID: 27569235
[TBL] [Abstract][Full Text] [Related]
10. Peroxiredoxins are involved in the pathogenesis of multiple sclerosis and neuromyelitis optica spectrum disorder.
Uzawa A; Mori M; Masuda H; Ohtani R; Uchida T; Aoki R; Kuwabara S
Clin Exp Immunol; 2020 Nov; 202(2):239-248. PubMed ID: 32643149
[TBL] [Abstract][Full Text] [Related]
11. Anti-C1q autoantibodies in patients with neuromyelitis optica spectrum disorders.
Yoshikura N; Kimura A; Hayashi Y; Inuzuka T
J Neuroimmunol; 2017 Sep; 310():150-157. PubMed ID: 28756870
[TBL] [Abstract][Full Text] [Related]
12. CSF high-mobility group box 1 is associated with intrathecal inflammation and astrocytic damage in neuromyelitis optica.
Uzawa A; Mori M; Masuda S; Muto M; Kuwabara S
J Neurol Neurosurg Psychiatry; 2013 May; 84(5):517-22. PubMed ID: 23255728
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures.
Jarius S; Paul F; Franciotta D; Ruprecht K; Ringelstein M; Bergamaschi R; Rommer P; Kleiter I; Stich O; Reuss R; Rauer S; Zettl UK; Wandinger KP; Melms A; Aktas O; Kristoferitsch W; Wildemann B
J Neurol Sci; 2011 Jul; 306(1-2):82-90. PubMed ID: 21550068
[TBL] [Abstract][Full Text] [Related]
14. Cytokines and Tissue Damage Biomarkers in First-Onset Neuromyelitis Optica Spectrum Disorders: Significance of Interleukin-6.
Wei Y; Chang H; Li X; Wang H; Du L; Zhou H; Xu W; Ma Y; Yin L; Zhang X
Neuroimmunomodulation; 2018; 25(4):215-224. PubMed ID: 30544111
[TBL] [Abstract][Full Text] [Related]
15. Elevated cerebrospinal fluid uric acid during relapse of neuromyelitis optica spectrum disorders.
Shu Y; Li H; Zhang L; Wang Y; Long Y; Li R; Qiu W; Lu Z; Hu X; Peng F
Brain Behav; 2017 Jan; 7(1):e00584. PubMed ID: 28127508
[TBL] [Abstract][Full Text] [Related]
16. Autocrine MMP-2/9 secretion increases the BBB permeability in neuromyelitis optica.
Tasaki A; Shimizu F; Sano Y; Fujisawa M; Takahashi T; Haruki H; Abe M; Koga M; Kanda T
J Neurol Neurosurg Psychiatry; 2014 Apr; 85(4):419-30. PubMed ID: 24259591
[TBL] [Abstract][Full Text] [Related]
17. Notable increased cerebrospinal fluid levels of soluble interleukin-6 receptors in neuromyelitis optica.
Wang H; Wang K; Zhong X; Dai Y; Qiu W; Wu A; Hu X
Neuroimmunomodulation; 2012; 19(5):304-8. PubMed ID: 22777162
[TBL] [Abstract][Full Text] [Related]
18. Systemic cellular immunity and neuroinflammation during acute flare-up in multiple sclerosis and neuromyelitis optica spectrum disorder patients.
Uchida N; Mori K; Fujita-Nakata M; Nakanishi M; Sanada M; Nagayama S; Sugiyama H; Matsui M
J Neuroimmunol; 2021 Apr; 353():577500. PubMed ID: 33592574
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid levels of iodothyronines and nerve growth factor in patients with multiple sclerosis and neuromyelitis optica.
Jiang Y; Yang Y; Zhang B; Peng F; Bao J; Hu X
Neuro Endocrinol Lett; 2009 Mar; 30(1):85-90. PubMed ID: 19300400
[TBL] [Abstract][Full Text] [Related]
20. Different blood-brain-barrier disruption profiles in multiple sclerosis, neuromyelitis optica spectrum disorders, and neuropsychiatric systemic lupus erythematosus.
Jasiak-Zatońska M; Pietrzak A; Wyciszkiewicz A; Więsik-Szewczyk E; Pawlak-Buś K; Leszczyński P; Kozubski W; Michalak S; Kalinowska-Łyszczarz A
Neurol Neurochir Pol; 2022; 56(3):246-255. PubMed ID: 35118639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
